A close and intriguing relationship has been suggested between heart failure (HF) and
coronavirus disease 2019 (COVID-19). First, COVID-19 pandemic represented a global …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Background: During the first wave of COVID-19, hydroxychloroquine (HCQ) was used off-
label despite the absence of evidence documenting its clinical benefits. Since then, a meta …

Objectives To investigate whether COVID-19 patients with pulmonary embolism had higher
mortality and assess the utility of d-dimer in predicting acute pulmonary embolism. Patients …

Major changes have occurred in these last years in heart failure (HF) management.
Landmark trials and the 2021 European Society of Cardiology guidelines for the diagnosis …

Background and aims Several studies reported a high incidence of pulmonary embolism
(PE) among patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) …

Aims We assessed the outcome of hospitalized coronavirus disease 2019 (COVID‐19)
patients with heart failure (HF) compared with patients with other cardiovascular disease …

Purpose To detect the risk factors for pulmonary embolism (PE) in patients with COVID-19.
Methods Studies were searched for in PubMed, Cochrane Library, Web of Science, and …

Pre-trained machine learning models have recently been widely used to detect COVID-19
automatically from X-ray images. Although these models can selectively retrain their layers …

Background: Protease inhibitors have been considered as possible therapeutic agents for
COVID-19 patients. Objectives: To describe the association between lopinavir/ritonavir …